Introduction: Medtech Innovation Is Hard Because Healthcare Is Hard
Medtech is one of the most important startup categories in the world.
A good medical device can change a patient’s life.
A better surgical tool can reduce complications.
A new diagnostic system can catch disease earlier.
A neurostimulation device can improve quality of life.
A cardiovascular innovation can prevent death.
A software-as-a-medical-device product can improve clinical decisions.
A robotic platform can make procedures more precise.
An AI-enabled tool can help overloaded clinicians act faster.
That is the promise.
But the market does not fund promise alone anymore.
Deloitte’s article, “Exploring alternative medtech investment strategies,” captures the reality of the sector. Medtech startups are facing harder traditional venture capital conditions, regulatory changes, reimbursement uncertainty, longer exit timelines, fewer IPOs, and investors who increasingly prefer later-stage companies.
That is not because medtech is unimportant.
It is because medtech is difficult.
A software startup can often launch, test, iterate, sell, and scale quickly.
A medtech startup has a different path.
Prototype.
Design controls.
Preclinical testing.
Clinical input.
FDA pathway.
Quality management system.
Biocompatibility.
Human factors.
Cybersecurity.
Manufacturing.
Clinical studies.
Regulatory submission.
Reimbursement strategy.
Hospital procurement.
Physician adoption.
Payer coverage.
Sales force.
Post-market monitoring.
Strategic acquisition.
That is a long road.
It is expensive.
It is risky.
It is slow.
And in a market where venture capital is more selective, investors now want more evidence before they write checks.
That is why alternative models such as build-to-buy, buy-to-build, co-development, structured deals, and corporate venture partnerships are becoming more important.
Medtech does not need less innovation.
It needs better capital design.
1. The 2021 Medtech Funding Peak Was Not Normal
Deloitte notes that medtech investment peaked in 2021, helped by pandemic-driven demand for digital tools, diagnostic solutions, and healthcare innovation.
That period created an unusual environment.
Healthcare systems were under pressure.
Digital health adoption accelerated.
Diagnostics became a public priority.
Remote care became more accepted.
Investors were flush with capital.
Interest rates were low.
IPO markets were open.
Venture capital was willing to fund more risk.
Many medtech and healthtech founders raised on aggressive assumptions.
But 2021 was not a normal baseline.
When interest rates rose, IPO windows closed, public market valuations corrected, and investors became more cautious, medtech funding slowed.
Fewer deals happened.
Exits became harder.
IPOs declined.
Early-stage startups struggled more.
Investors shifted toward later-stage companies with clearer evidence.
This is the first lesson for founders:
Do not build your financing plan around the easiest year in recent history.
Build for the market that exists now.
2. Medtech Funding Did Not Disappear. It Became More Selective.
The current medtech market is not dead.
It is selective.
That distinction matters.
Strong companies can still raise.
Companies with clinical validation can still attract capital.
Strategic acquirers are still active.
AI-enabled healthcare tools are attracting attention.
Cardiovascular, neurostimulation, connected care, surgical robotics, medical software, and brain-computer interface companies can still find investors.
But the bar is higher.
Investors now want:
Clinical results.
Regulatory visibility.
Reimbursement logic.
Commercial traction.
Health-system adoption.
Quality systems.
Strong governance.
Clear milestones.
Strategic relevance.
Exit path.
This is a more mature funding environment.
It does not reward invention alone.
It rewards de-risking.
That is the word every medtech founder should remember.
De-risk the product.
De-risk the clinical pathway.
De-risk regulation.
De-risk reimbursement.
De-risk manufacturing.
De-risk adoption.
De-risk the exit.
Each round should reduce a specific risk.
3. The Early-Stage Gap Is the Most Dangerous Part of the Market
Deloitte says investors are now focusing more on mature companies, making early-stage funding scarcer.
This is one of the biggest problems in medtech.
If early-stage companies cannot raise enough capital, the innovation pipeline weakens.
This matters not only to founders, but also to large medtech companies.
Strategic acquirers depend on startups to create differentiated technologies and future acquisition targets. If early-stage formation slows, future M&A pipelines suffer.
The early-stage gap exists because medtech is expensive before revenue.
A founder may need capital for:
Prototype development.
Animal studies.
Design controls.
Regulatory consultants.
Quality systems.
Engineering.
Clinical advisors.
Usability testing.
Manufacturing partners.
FDA submissions.
Pilot clinical studies.
Hospital relationships.
The company may not have revenue for years.
That is hard for generalist venture investors.
It is why medtech often needs specialist capital, strategic partnerships, non-dilutive grants, venture debt only at later stages, and milestone-based financing.
Early-stage medtech investors must understand the science, device pathway, clinical use case, reimbursement logic, and strategic buyer universe.
Generic venture capital is often not enough.
4. Medtech Is Not SaaS
Many investors and founders make the mistake of comparing medtech to software.
That is dangerous.
A SaaS startup can often change code quickly.
A medtech startup cannot freely change a regulated device after submission without considering regulatory impact.
A SaaS startup can sell directly to business buyers.
A medtech startup may need physician adoption, hospital procurement, payer coverage, coding, clinical evidence, and regulatory approval.
A SaaS startup can test pricing quickly.
A medtech startup may face reimbursement constraints.
A SaaS startup can launch a minimum viable product.
A medtech startup may need a safe, validated, clinically appropriate product before real use.
A SaaS startup can grow with inside sales.
A medtech startup may need field sales, clinical training, KOL support, and hospital implementation.
This does not make medtech worse.
It makes it different.
Founders must understand that investors will not evaluate a medical device startup the same way they evaluate a productivity software company.
The milestone map is different.
The risk stack is different.
The capital stack is different.
The exit path is different.
5. FDA Clearance Is Necessary, but Not Sufficient
Many medtech founders focus heavily on FDA clearance or approval.
That is understandable.
Regulatory permission is a major milestone.
But FDA clearance alone does not create a business.
A device can be cleared and still fail if:
Clinicians do not adopt it.
Hospitals do not buy it.
Payers do not reimburse it.
Workflow integration is difficult.
Training burden is too high.
The product does not improve outcomes enough.
The economic buyer is unclear.
The sales cycle is too long.
Manufacturing costs are too high.
Margins are weak.
Strategic acquirers are not interested.
The founder must understand the difference between regulatory success and commercial success.
Investors know this.
That is why they ask about reimbursement and market access early.
A strong medtech company should be able to answer:
What is the regulatory pathway?
What evidence is required?
What is the reimbursement pathway?
Who pays?
Who uses it?
Who decides?
Who benefits economically?
What code, coverage, or payment mechanism exists?
What clinical workflow changes?
What training is required?
What evidence will convince a hospital?
What evidence will convince an acquirer?
Regulatory strategy is one part of the company.
Not the whole company.
6. Reimbursement Is Often the Real Valley of Death
Deloitte emphasizes reimbursement uncertainty as one of the major challenges facing medtech startups.
This may be the most important commercial issue in the sector.
A device can work clinically and still fail economically.
Reimbursement determines whether the healthcare system can pay for it.
Founders must understand:
Is there an existing CPT code, HCPCS code, DRG, or payment pathway?
Is the device separately reimbursed or bundled?
Does the hospital absorb the cost?
Does the physician benefit?
Does the payer see cost savings?
Does Medicare matter?
Do commercial payers matter?
Is coverage local, national, or payer-specific?
What evidence is needed?
Will the device increase cost before reducing cost?
Does the device create revenue for the provider?
Does it reduce complications, length of stay, readmissions, staffing burden, or procedure time?
Reimbursement is not an afterthought.
It is part of product strategy.
A medtech founder should design the product, clinical evidence plan, and go-to-market strategy with reimbursement in mind.
A device without a reimbursement path may still be valuable, but the founder must explain who pays and why.
7. CMS TCET May Help, but It Does Not Remove the Evidence Burden
The U.S. Centers for Medicare & Medicaid Services finalized the Transitional Coverage for Emerging Technologies pathway for certain FDA-designated Breakthrough Devices.
This matters because coverage uncertainty has long been a major challenge for breakthrough medtech companies.
The TCET pathway is designed to use national coverage determination and coverage with evidence development processes to help provide more predictable and expedited Medicare coverage for certain eligible devices.
This is helpful.
But founders should not misunderstand it.
TCET is not a free pass.
It does not eliminate the need for evidence.
It does not guarantee broad commercial success.
It does not replace clinical validation.
It does not solve every reimbursement problem.
It helps create a pathway for certain breakthrough devices, especially where Medicare access is relevant.
The deeper lesson is that reimbursement planning is becoming more structured and more important.
A founder building a breakthrough device should think about FDA, CMS, coverage, evidence development, and commercial payer strategy as connected systems.
8. Build-to-Buy Is Gaining Traction Because Medtech Risk Is Too Hard to Hold Alone
Deloitte highlights build-to-buy models as a major alternative financing strategy.
In a build-to-buy arrangement, a strategic medtech company partners with a startup early, helps fund or co-develop the product, and often retains an option to acquire the company if milestones are met.
This model makes sense.
The startup gets:
Capital.
Strategic validation.
Regulatory expertise.
Manufacturing knowledge.
Clinical input.
Commercial guidance.
Potential distribution.
A clearer exit path.
The strategic company gets:
Access to innovation.
Reduced technical risk.
A view into the team.
Milestone-based optionality.
A possible future acquisition.
Portfolio gap coverage.
A way to avoid overpaying after the company is fully de-risked.
Medtech is well suited to build-to-buy because strategic buyers often understand the market better than generalist investors.
They know what product gaps exist.
They know what physicians want.
They understand regulatory and reimbursement pathways.
They know manufacturing requirements.
They know the acquisition criteria.
But build-to-buy also has risks.
The startup may become too dependent on one buyer.
The option structure may limit future exit competition.
The strategic partner may slow the company down.
The startup may lose leverage.
The deal may create conflicts with other investors.
The founder must negotiate carefully.
Build-to-buy can be powerful, but only when incentives are aligned.
9. Buy-to-Build Is Another Sign That Strategic Buyers Want More Control
Deloitte also describes buy-to-build models, where strategic investors or private equity firms identify product gaps and acquire or form companies to fill them.
This is different from waiting for startups to mature.
It is a more active company-creation or platform-building model.
A strategic acquirer may say:
We need a cardiovascular product in this category.
We need connected-care capability.
We need AI-enabled software around our device portfolio.
We need surgical robotics exposure.
We need neurostimulation assets.
We need a platform in diagnostics.
Then it buys or builds around that gap.
This model is attractive because large companies cannot rely only on organic R&D.
They need external innovation.
But they also want to reduce risk.
Buy-to-build lets them shape the innovation pipeline more deliberately.
For founders, this means strategic relevance matters.
A medtech startup should understand which strategic buyers have portfolio gaps and what evidence they need before acquisition.
Do not build in isolation.
Build with the future buyer map in mind.
10. Hybrid and Structured Deals Are Becoming More Common
Deloitte notes that medtech funding often blends traditional venture capital with alternative sources and structured arrangements.
This is logical because medtech risk is multi-layered.
A single financing instrument may not fit all stages.
A medtech company might use:
Seed equity.
Angel capital.
Non-dilutive grants.
University translational funding.
Strategic co-development.
Corporate venture capital.
Milestone-based tranches.
Venture debt later.
Royalty financing.
Licensing.
Build-to-buy option.
Private equity platform capital.
M&A.
The founder needs capital-stack literacy.
This is especially true when the company has hardware, clinical trials, manufacturing, regulatory work, and long sales cycles.
Equity is not always enough.
Debt may be too risky early.
Strategic capital may be useful but restrictive.
Grants may help but not replace market validation.
Structured deals may unlock financing but complicate governance.
The best medtech founders understand the financing tool and the risk being financed.
11. Governance Can Make or Break a Medtech Startup
Deloitte emphasizes governance, leadership, milestone tracking, and incentive systems.
This is not a generic point.
Medtech companies are complex.
They involve founders, clinicians, engineers, investors, regulatory advisors, quality experts, strategic partners, hospitals, and potential acquirers.
Without clear governance, friction rises.
Who makes product decisions?
Who owns clinical strategy?
Who controls regulatory strategy?
Who manages the strategic partner?
Who decides when to pivot?
Who manages milestones?
Who communicates with investors?
Who runs the company?
Deloitte specifically notes that having a single CEO helps minimize friction.
That matters.
Medtech startups often begin around scientific, clinical, or engineering founders. Those founders may be brilliant, but the company still needs a clear operating leader.
Investors want to know who is accountable.
Strategic partners want one decision-maker.
Employees need clarity.
Regulators need consistency.
Hospitals need confidence.
Governance is not bureaucracy.
It is the operating system for trust.
12. Incentives Matter More in Structured Deals
When a startup enters a build-to-buy or co-development deal, incentives become complicated.
The startup wants to maximize future value.
The strategic partner wants to reduce acquisition risk.
Investors want a return.
Employees want upside.
Clinicians want the product to work.
Patients need safety.
A bad incentive structure can damage the company.
If acquisition terms are too predetermined, the startup may lose upside.
If milestones are too vague, disputes arise.
If the strategic partner has too much control, other investors may hesitate.
If the team lacks equity motivation, execution suffers.
If the company cannot sell to other buyers, exit value may be capped.
A strong deal should define:
Milestones.
Funding tranches.
Decision rights.
IP ownership.
Data rights.
Exclusivity.
Acquisition option terms.
Governance.
Employee incentives.
Exit alternatives.
Dispute process.
Structured deals are useful only when structure supports growth.
Bad structure can trap innovation.
13. Investors Now Prefer Clinical Validation and Market Readiness
Deloitte says funding is shifting toward later-stage companies with demonstrated clinical results and market readiness.
This is the new medtech funding logic.
Investors want to reduce uncertainty before writing larger checks.
Clinical validation matters because it shows the device works in relevant conditions.
Regulatory visibility matters because it shows the company can legally reach market.
Market readiness matters because it shows customers may adopt.
Commercial traction matters because it shows the product is not only technically interesting.
The problem is that many startups need capital before they can prove all of this.
That is the early-stage gap.
Founders must therefore design staged milestones.
At pre-seed or Seed:
Clear unmet need.
Strong clinical advisory support.
Prototype.
IP.
Regulatory pathway assessment.
Reimbursement hypothesis.
Early user feedback.
At Series A:
Design freeze direction.
Preclinical or early clinical evidence.
Quality system foundation.
FDA pre-submission feedback if relevant.
Manufacturing plan.
Better reimbursement analysis.
At Series B:
Clinical validation.
Regulatory submission or path.
Pivotal trial progress.
Strategic buyer interest.
Commercial pilot readiness.
At growth stage:
Regulatory clearance or approval.
Revenue.
Reimbursement progress.
Sales model.
Manufacturing scale.
Acquirer-ready data.
This is how founders should think.
Each round must buy risk reduction.
14. Cardiovascular Devices Remain Attractive Because the Need Is Enormous
Deloitte and PwC both note investor and buyer interest in cardiovascular devices.
That makes sense.
Cardiovascular disease remains one of the largest healthcare burdens globally.
Devices that improve diagnosis, intervention, monitoring, surgery, structural heart care, electrophysiology, heart failure management, or vascular treatment can address enormous markets.
But cardiovascular devices are hard.
They often require strong clinical evidence.
Procedure integration.
Physician training.
Regulatory rigor.
Reimbursement clarity.
Hospital economics.
Manufacturing quality.
Strategic buyer alignment.
The opportunity is large because the need is large.
But investors will not fund vague cardiovascular innovation.
They want evidence that the device can improve outcomes, fit workflows, and become commercially adoptable.
15. Neurostimulation and Brain Tech Are Hot, but Require Careful Evidence
Neurostimulation and brain technology remain active areas of investor interest.
The market includes devices for:
Pain.
Movement disorders.
Epilepsy.
Depression.
Sleep.
Cognitive disorders.
Alzheimer’s-related diagnostics and intervention.
Brain-computer interfaces.
Neurorehabilitation.
These areas are exciting because unmet need is high and technology is advancing.
But they are also difficult.
Endpoints can be complex.
Clinical adoption can be cautious.
Regulatory pathways may vary.
Long-term safety matters.
Reimbursement can be challenging.
Patients may be vulnerable.
Investors need to see more than technical novelty.
They need evidence that the technology can deliver reliable clinical benefit and fit the care model.
Brain tech is not a hype category.
It is a proof category.
16. Medical Software and AI-Enabled Devices Are Rising, but Trust Is the Product
Medical software and AI-enabled tools are attracting investor attention.
That includes:
Radiology AI.
Clinical decision support.
Surgical planning.
Remote monitoring.
Patient triage.
Workflow automation.
Diagnostics.
Hospital operations.
Clinical documentation.
Predictive analytics.
Software as a medical device.
The FDA maintains an AI-enabled medical device list to identify AI-enabled devices authorized for marketing in the United States.
This shows that AI-enabled medical devices are becoming a real regulatory and commercial category.
But AI in healthcare has a trust problem.
Clinicians need confidence.
Hospitals need validation.
Regulators need safety evidence.
Patients need protection.
Payers need value.
Founders must prove:
Clinical performance.
Generalizability.
Bias monitoring.
Cybersecurity.
Workflow fit.
Human oversight.
Liability strategy.
Post-market monitoring.
Model update governance.
AI is powerful in healthcare, but healthcare is unforgiving.
A wrong answer can harm a patient.
That is why trust is not a marketing message.
Trust is the product.
17. Predetermined Change Control Plans Matter for AI Medical Devices
AI-enabled medical devices create a unique challenge.
Software can improve over time.
Models may need updates.
Data drift can happen.
Clinical environments differ.
But medical devices are regulated.
This creates tension: how can AI improve without creating uncontrolled safety risk?
The FDA has created guidance around Predetermined Change Control Plans for AI-enabled device software functions, allowing manufacturers to define certain future modifications in advance.
This is important because adaptive medical AI needs lifecycle governance.
Founders building AI medical devices should think early about:
What changes may be needed?
How will performance be monitored?
How will drift be detected?
What data supports updates?
What human review is required?
What post-market surveillance exists?
How will the company document changes?
How will regulators, clinicians, and customers trust updates?
An AI medtech company is not finished at clearance.
It must operate safely after deployment.
18. Robotics Can Attract Capital, but Field Performance Matters
Robotics is one of the most exciting medtech categories.
Surgical robotics.
Rehabilitation robotics.
Procedure assistance.
Hospital automation.
Micro-robotics.
Interventional platforms.
Robotic imaging.
Investors like robotics because it combines hardware, software, AI, precision, workflow transformation, and strategic buyer interest.
But robotics is expensive.
A robotics startup must prove:
Clinical value.
Safety.
Reliability.
Procedure efficiency.
Training requirements.
Capital equipment economics.
Consumable revenue model.
Surgeon adoption.
Hospital ROI.
Service and maintenance.
Manufacturing scalability.
A robot that looks impressive in a demo may still fail in the operating room or procurement committee.
Robotics founders must sell outcomes, not machinery.
19. Hospitals Are Not Normal Customers
Medtech go-to-market is hard because hospitals are complex buyers.
A hospital purchase may involve:
Clinicians.
Department heads.
Procurement.
Finance.
Value analysis committees.
IT.
Cybersecurity.
Compliance.
Payers.
Administrators.
Nursing leadership.
Supply chain.
Risk management.
Training teams.
A founder may convince the physician but lose the finance committee.
Or win clinical interest but fail cybersecurity review.
Or prove outcome improvement but lack reimbursement.
Or secure a pilot but never convert to system-wide adoption.
This is why Deloitte emphasizes specialized sales teams and multiple health-system stakeholders.
Medtech founders must understand the buyer map.
Who uses it?
Who pays?
Who approves?
Who blocks?
Who benefits?
Who trains?
Who maintains?
Who measures value?
Hospital sales is not one sale.
It is a coalition sale.
20. Clinician Innovation Is Under Pressure
Deloitte notes that medtech innovations decline as clinicians face increasing financial pressure.
This is an underappreciated issue.
Many medtech ideas begin with clinicians.
Surgeons.
Interventional cardiologists.
Radiologists.
Nurses.
Emergency physicians.
Specialists.
They see problems every day.
But clinicians are under pressure.
Burnout.
Administrative burden.
Hospital economics.
Time constraints.
Productivity demands.
Reimbursement pressure.
Staffing shortages.
Less time for invention.
Less support for translation.
If clinicians cannot participate in innovation, the pipeline weakens.
Ecosystems should support clinician founders through:
Protected innovation time.
Hospital innovation offices.
Prototype support.
Regulatory education.
IP support.
Startup formation help.
Clinical validation pathways.
Medtech accelerators.
Industry partnerships.
Founder-friendly university policies.
The best medtech ideas often come from the people closest to the patient.
The ecosystem must help them build.
21. Strategic Acquirers Still Need Startups
Large medtech companies depend on external innovation.
They cannot build everything internally.
They need startups for:
New devices.
New indications.
AI-enabled workflow tools.
Robotics.
Connected care.
Digital platforms.
Diagnostics.
Specialty devices.
Adjacency expansion.
Portfolio renewal.
PwC notes that strategic partnerships, corporate venture investment, and M&A are becoming increasingly important to scaling emerging technologies and supporting future innovation pipelines.
This is important because venture funding constraints do not only hurt startups.
They hurt acquirers.
If early-stage startups cannot develop, future strategic acquisition targets disappear.
This creates a reason for strategic acquirers to invest earlier through build-to-buy, CVC, co-development, and partnership models.
Strategic acquirers should not wait until startups are fully de-risked.
By then, the best assets may be expensive or unavailable.
22. M&A Is Active, but Buyers Are Selective
Medtech M&A remains active, but buyers are not buying everything.
They are focused on assets that strengthen long-term strategic positioning.
PwC says buyers are focused on durable growth, differentiated technology, long-term category leadership, operational resilience, and integration readiness.
That means founders must build for strategic fit.
An acquirer wants to know:
Does this fit our portfolio?
Can our sales force sell it?
Does it expand a category we care about?
Does it improve clinical outcomes?
Does it strengthen connected care?
Does it create data advantage?
Can we integrate manufacturing?
Can we handle reimbursement?
Can we scale globally?
Can we defend the IP?
Can this become meaningful revenue?
M&A is not a bailout.
It is a strategic decision.
Founders who understand buyer logic can design better companies.
23. IPOs Are Reopening Slowly, but Medtech Cannot Rely on Them Alone
The medtech IPO market has shown signs of reopening, but not broadly.
The market is still selective.
A small number of strong companies can list.
Most startups still need to plan for strategic acquisition, structured deals, or longer private-company timelines.
This affects fundraising.
If investors believe IPO is unlikely, they will ask:
Who buys this company?
When?
At what milestone?
At what valuation?
What evidence is needed?
Which acquirers care?
What precedent transactions exist?
What strategic gap does it fill?
Medtech founders should think about exit path earlier than software founders sometimes do.
Not because they should build only to sell.
But because medtech venture returns often depend on acquisition.
Build a company patients need.
But understand who may eventually scale it.
24. Early-Stage Medtech Needs More Than Money
Money matters.
But medtech startups need more than money.
They need:
Regulatory expertise.
Clinical advisors.
Quality system support.
Reimbursement strategy.
Manufacturing partners.
KOL relationships.
Hospital access.
Human factors testing.
Cybersecurity support.
Sales model design.
Strategic buyer knowledge.
Governance.
This is why specialist investors matter.
A generalist investor may provide capital, but not know how to help the company cross the medtech valley of death.
A strong medtech investor can help with milestone planning, regulatory strategy, clinical design, strategic introductions, and exit positioning.
Founder advice:
Do not choose investors only by check size.
Choose investors who understand your risk path.
25. Private Equity Is Filling Some Gaps, but Mostly Later
Deloitte notes that private equity is filling some gaps, but mainly for later-stage deals.
This makes sense.
Private equity generally prefers more mature assets.
Revenue.
EBITDA potential.
Commercial traction.
Platforms.
Add-on acquisition opportunities.
Operational improvement.
PE can be useful in medtech when a company has commercial traction and can be scaled, professionalized, or combined with other assets.
But PE is usually not the answer for early invention risk.
It is less likely to fund a device before clinical validation.
That means the early-stage gap still needs venture capital, strategic capital, grants, and co-development models.
PE can help later.
It cannot replace the whole innovation pipeline.
26. Medtech Founders Must Build the Evidence Package for Investors and Acquirers
A strong medtech startup needs an evidence package.
That package should include:
Unmet clinical need.
Physician and patient pain.
Market size.
Regulatory pathway.
Clinical evidence plan.
Reimbursement strategy.
Health economics.
Prototype performance.
IP position.
Freedom to operate.
Quality system plan.
Manufacturing plan.
KOL support.
Hospital adoption strategy.
Cybersecurity plan if software-connected.
Strategic buyer map.
Milestone-based financing plan.
This evidence package should improve over time.
At every round, the founder should be able to say:
Here is the risk we removed.
Here is the risk that remains.
Here is what this round will prove.
That is how medtech fundraising works in a selective market.
27. AI Medtech Founders Must Prove ROI, Not Only Accuracy
AI medical devices and healthcare AI startups often focus on accuracy metrics.
Sensitivity.
Specificity.
AUC.
False positives.
False negatives.
Those metrics matter.
But commercial success also requires ROI.
Does the tool reduce clinician workload?
Does it improve throughput?
Does it reduce missed diagnoses?
Does it reduce length of stay?
Does it reduce avoidable procedures?
Does it help triage faster?
Does it improve billing accuracy?
Does it reduce malpractice risk?
Does it fit existing workflow?
Can hospitals justify the purchase?
A technically accurate AI tool can still fail if it does not fit workflow or economics.
AI medtech founders must prove clinical and financial value.
28. Cybersecurity Is Now Part of Medtech Value
Connected devices, AI software, remote monitoring, cloud systems, and hospital integrations create cybersecurity risk.
Medtech founders must treat cybersecurity seriously.
Hospitals will ask about it.
Regulators may require it.
Acquirers will diligence it.
Patients depend on it.
A connected medical device should not be designed as if cybersecurity can be added later.
Founders should consider:
Data security.
Access controls.
Software updates.
Device integrity.
Threat modeling.
Vulnerability management.
Post-market monitoring.
Hospital IT integration.
Incident response.
Cybersecurity is not only a compliance issue.
It is part of clinical trust.
29. Manufacturing Is a Venture Risk
Many medtech founders underestimate manufacturing.
A device that works in prototype form may be difficult to manufacture reliably at scale.
Investors will ask:
Can it be produced consistently?
What is the cost of goods?
Who manufactures it?
What quality system exists?
What supply-chain risks exist?
Can components be sourced reliably?
Can margins support sales and distribution?
Can production meet regulatory requirements?
What happens if demand increases?
Manufacturing risk is especially important for hardware, robotics, implants, diagnostics, and consumables.
A founder must understand the path from prototype to manufacturable product.
That path is often where companies fail.
30. Canada’s Medtech and Healthtech Market Has the Same Pattern: Narrow Recovery, Exits Lag
Canada’s healthtech and life sciences market shows similar dynamics.
Canadian healthtech funding rebounded in 2025, but the recovery was narrow and concentrated in fewer, larger, higher-conviction rounds.
Pender Ventures’ Canadian Health Tech Funding and Trends Report says 2025 funding reached about $1.3 billion, up 65% year over year, but deal count fell 32% to 351. Late-stage still captured about 65% of invested capital, and exits remained weak, with no TSX or TSXV IPOs.
That is the same pattern seen globally:
More capital for companies with proof.
Less broad early-stage risk appetite.
Harder exit conditions.
More pressure to be strategically relevant.
For Canadian founders, this means the company must be built to global standards earlier.
Regulatory strategy.
Clinical validation.
Reimbursement.
U.S. market access.
Strategic buyer relationships.
Canadian healthtech cannot rely only on domestic funding.
Many companies will need U.S. customers, U.S. investors, or global strategic acquirers.
31. Canada’s Value-Capture Problem Applies to Medtech Too
Canada has strong life sciences research and health technology talent.
But adMare warns that much of the economic value and IP generated by Canadian life sciences flows abroad because domestic capital participation declines as companies grow.
This is a major issue.
If Canadian investors support early science, but later-stage funding and exit returns flow mainly to international investors, Canada becomes a source of innovation but not a long-term owner of value.
For medtech, the same risk exists.
Canadian founders may develop promising devices, software, diagnostics, or platforms, but need U.S. capital and U.S. buyers to scale.
That is not inherently bad.
Global capital is useful.
But Canada should build more domestic scale capacity:
Medtech-focused funds.
Hospital procurement pathways.
Clinical trial infrastructure.
Device manufacturing support.
Domestic growth capital.
Strategic corporate partnerships.
Pension fund participation.
Better university commercialization.
Health system innovation procurement.
Canada cannot capture more value if its own health systems and investors do not help companies scale.
32. The USA Remains the Most Important Medtech Market
The United States remains the center of gravity for medtech because it has:
Large healthcare spending.
FDA regulatory pathway.
Major medtech strategic acquirers.
Specialist investors.
Large hospital systems.
Strong academic medical centers.
Reimbursement complexity, but also reimbursement opportunity.
Large commercial payer market.
Medicare.
Deep capital markets.
M&A buyers.
Clinical trial infrastructure.
For global medtech startups, the U.S. market often matters even if the company begins elsewhere.
But the U.S. is difficult.
The market is large, but fragmented.
The regulatory path is demanding.
Reimbursement is complex.
Hospital procurement is slow.
Sales is expensive.
Evidence expectations are high.
A founder entering the U.S. must be prepared.
The U.S. market rewards medtech companies that can prove value.
It punishes those that assume clinical novelty is enough.
33. The Founder Playbook for Medtech Fundraising
Medtech founders should follow a disciplined playbook.
1. Start with clinical need, not technology
The problem should be painful, frequent, expensive, and clearly understood.
2. Map the regulatory pathway early
Know whether the device is likely 510(k), De Novo, PMA, or another pathway.
3. Build reimbursement strategy from the beginning
Do not wait until after clearance.
4. Validate workflow fit
Physicians and hospitals must be able to adopt the product.
5. Design milestones for each round
Every financing should remove a specific risk.
6. Choose specialist investors
Medtech experience matters.
7. Build strategic buyer relationships early
Do not wait until exit to learn what acquirers want.
8. Consider build-to-buy carefully
It can derisk the path, but negotiate control, IP, and exit terms carefully.
9. Build governance early
Investors need leadership clarity, milestone tracking, and incentive alignment.
10. Prepare for a long timeline
Medtech takes longer and costs more than many founders expect.
34. The Investor Playbook
Medtech investors should also adjust.
1. Underwrite risk by milestone
Do not fund vague progress. Fund risk reduction.
2. Support early-stage companies with expertise
Capital alone is not enough.
3. Build strategic relationships
Acquirer insight improves investment judgment.
4. Understand reimbursement
A device without payment logic may struggle.
5. Evaluate workflow adoption
Clinical value must fit real healthcare operations.
6. Be cautious with AI hype
Accuracy is not the same as adoption or ROI.
7. Use structured deals wisely
Milestones can align risk, but bad structure can trap the company.
8. Help with governance
Medtech leadership and board quality matter.
9. Think globally
Many medtech companies need U.S., European, and international strategies.
10. Protect the early-stage pipeline
Without early-stage capital, future M&A dries up.
35. The Strategic Acquirer Playbook
Large medtech companies should not wait passively for startups to become acquisition-ready.
They should:
Map portfolio gaps.
Build CVC capabilities.
Use build-to-buy selectively.
Offer co-development support.
Provide regulatory and manufacturing expertise.
Run paid pilots.
Support clinical validation.
Avoid over-controlling startups.
Create clear acquisition criteria.
Maintain external innovation pipelines.
Strategic acquirers need startups.
The healthiest medtech companies will be those that build strong external innovation networks.
36. The Hospital and Health System Playbook
Hospitals are not just customers.
They are innovation gatekeepers.
They can help medtech startups by:
Providing clinical feedback.
Running pilots.
Supporting evidence generation.
Helping evaluate workflow fit.
Offering procurement clarity.
Participating in value analysis.
Giving startup-friendly feedback.
Avoiding endless unpaid pilots.
Supporting clinician innovators.
Health systems need innovation, but they must make adoption pathways clearer.
A startup cannot survive years of pilots with no purchasing decision.
37. The Policy Playbook
Policymakers can strengthen medtech innovation by improving:
Regulatory predictability.
Coverage pathways.
Reimbursement clarity.
Clinical trial infrastructure.
Startup-friendly procurement.
Hospital innovation funding.
Non-dilutive grants.
Device manufacturing support.
AI medical device governance.
Cybersecurity standards.
University commercialization.
Early-stage translational funding.
Medtech is strategically important.
It affects health outcomes, national competitiveness, manufacturing, aging populations, and healthcare productivity.
Policy should support serious innovation, not only research publication.
38. The Future of Medtech Venture Capital
The future medtech market will likely be shaped by several forces.
Later-stage concentration
More capital will go to companies with clinical, regulatory, and commercial proof.
Strategic partnerships
Build-to-buy, co-development, CVC, and structured deals will become more common.
AI-enabled devices
Medical software and AI tools will grow, but only those with workflow ROI and regulatory credibility will win.
Robotics and procedural innovation
Surgical and interventional platforms will attract interest but require serious capital and proof.
Reimbursement discipline
Payment strategy will be a core diligence issue.
M&A-driven exits
Strategic acquirers will remain central.
Health-system adoption pressure
Products must fit real clinical and economic workflows.
Global competition
The U.S. will remain central, but Canada, Europe, China, India, Israel, and other ecosystems will continue producing innovation.
The market is not closed.
It is professionalizing.
Conclusion: Medtech Needs Better Capital Models, Not Less Ambition
Deloitte’s medtech investment article makes one thing clear:
The old venture model is not enough for every medtech company.
Funding has become harder since the 2021 peak.
Investors are more cautious.
Early-stage capital is scarcer.
Exits take longer.
IPO markets reopen unevenly.
Regulatory and reimbursement uncertainty remain major barriers.
Hospitals are difficult customers.
Clinicians are under pressure.
Strategic acquirers still need innovation, but they want de-risked assets.
That is why alternative models are gaining traction.
Build-to-buy.
Buy-to-build.
Co-development.
Structured deals.
Strategic partnerships.
Corporate venture capital.
Private equity platform-building.
These models are not perfect.
They require strong governance, aligned incentives, clear milestones, and careful negotiation.
But they recognize the truth of medtech:
This is not a normal startup category.
Medtech founders are not only building products.
They are navigating healthcare systems.
They must prove safety, effectiveness, adoption, payment, manufacturing, quality, and strategic relevance.
The best medtech founders will not complain that investors are demanding more proof.
They will build the proof.
Clinical proof.
Regulatory proof.
Reimbursement proof.
Commercial proof.
Workflow proof.
Strategic proof.
The best investors will not abandon early-stage medtech.
They will finance it intelligently.
The best acquirers will not wait until innovation is fully de-risked by someone else.
They will help build it.
The best ecosystems will support clinician innovators, regulatory readiness, reimbursement strategy, device manufacturing, and hospital adoption.
Medtech is hard because healthcare is hard.
But that is exactly why great medtech companies matter.
They do not just create returns.
They improve care.
And the founders who learn how to build through complexity will be the ones who bring the next generation of medical innovation from idea to patient.